SFDA To Speed Up Evaluation Of Registered Drugs
This article was originally published in PharmAsia News
To solve the problem of evaluating a huge backlog of registered drugs, China's State FDA has begun a centralized drug evaluation strategy since January to handle approved but overdue applications before the revised Drug Registration Regulation becomes effective. The new approach is divided into two stages: January to April 2008 was the data comparison stage where SFDA sieved out registration applications with similar information, content or fabricated data to ensure authenticity; April to September 2008 is the technical evaluation stage where experts meet to adopt centralized review techniques and methods in new drug development. (Click here for more - Chinese Language)
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.